Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Marcela V Maus"'
Autor:
Matan Hofree, Robert Morris, Nemanja D. Marjanovic, Joshua Gould, Caroline B. M. Porter, Kirk Gosik, Orr Ashenberg, Ana P. Castano, Marcela V. Maus, Lauren S. Riley, Selena J. Lorrey, Samantha J. Riesenfeld, Rebecca C. Larson, Bryan D. Choi, Livnat Jerby, Trisha R. Berger, Gabriela Smith-Rosario, Aviv Regev, Angela C. Boroughs, Orit Rozenblatt-Rosen
Publikováno v:
Mol Ther
T cells engineered to express chimeric antigen receptors (CARs) targeting CD19 have produced impressive outcomes for the treatment of B cell malignancies, but different products vary in kinetics, persistence, and toxicity profiles based on the co-sti
Autor:
Marcela V. Maus, Matthew J. Frigault
Publikováno v:
J Clin Invest
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell ma
Autor:
Michael Kann, Stefanie R. Bailey, Amanda A. Bouffard, Irene Scarfò, Max Jan, Julia Joung, Travis Law, Mark B. Leick, Gad Getz, Tamara Ouspenskaia, Rebecca C. Larson, Nicholas J. Haradhvala, Marcela V. Maus, Aviv Regev, Kai Stewart, Trisha R. Berger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundChimeric Antigen Receptor (CAR) therapy has had a transformative impact on the treatment of hematologic malignancies1–6 but success in solid tumors remains elusive. We hypothesized solid tumors have cell-intrinsic resistance mechanisms to
Autor:
Marcello Stanzione, Songfa Zhang, Nicholas J. Dyson, John F. Rawls, Eric J Alpert, David Millar, Daniel Do, David M. Langenau, Yun Wei, Benjamin J. Drapkin, Irene Scarfò, John C. Moore, Qian Qin, Alexandra Veloso, Qiqi Yang, Dalton C. Brunson, Karin M. McCarthy, Marcela V. Maus, Chuan Yan, Mark Cobbold, Sowmya Iyer
Publikováno v:
The Journal of Experimental Medicine
Xenograft cancer studies using rag2Δ/Δ, il2rga−/− zebrafish allow facile, single-cell imaging of T cell–mediated tumor killing by CAR T cell, BiTE, and APEC immunotherapies and identified EGFR-targeted immunotherapies as an effective treatmen
Autor:
Gabrielle Brini, Jennifer Y. Yam, Kathleen Gallagher, Katelin Katsis, Rebecca C. Larson, Trisha R. Berger, Mark B. Leick, Marcela V. Maus, Korneel Grauwet
Publikováno v:
bioRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
SUMMARYRecently, two mRNA vaccines to severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) have become available, but there is also an emergence of SARS-CoV-2 variants with increased transmissibility and virulence1–6. A major concern is wh
Autor:
Joseph S. Durgin, Fraser Henderson, MacLean P. Nasrallah, Suyash Mohan, Sumei Wang, Simon F. Lacey, Jan Joseph Melenhorst, Arati S. Desai, John Y. K. Lee, Marcela V. Maus, Carl H. June, Steven Brem, Roddy S. O’Connor, Zev Binder, Donald M. O’Rourke
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor receptor variant III (CAR T-EGFRvIII) have been developed and administered experimentally to treat patients with IDH1 wildtype recurrent glioblastoma (rGBM) (NCT02
Autor:
Regina M. Myers, Carl H. June, David M. Barrett, Stephan A. Grupp, Rong Fan, J. Joseph Melenhorst, Pablo G. Camara, Dong-Joo Kim, Marcela V. Maus, Stefan Lundh, Steven Woodhouse, Zhiliang Bai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAutologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 molecule have transformed the therapeutic landscape in patients with highly refractory leukemia and lymphoma, and the use of donor-generated alloge
Autor:
Jennifer Y. Yam, Victoria Burgoyne, Kathleen Gallagher, Ulrika Johansson, Marcela V. Maus, Gabrielle Brini, Keagan S Casey, Nikesh Chavda, Sanne Lugthart, Caroline Besley, Matthew J. Frigault
Publikováno v:
Cytometry. Part B, Clinical cytometryREFERENCES. 100(6)
BACKGROUND Chimeric antigen receptor-modified T-cells targeting CD19 (CAR-T19) are licensed for treating relapsed/refractory diffuse large B-cell lymphoma and B-acute lymphoblastic leukemia. Predicting treatment responses and toxicity (e.g., cytokine
Autor:
Bryan D. Choi, Shadmehr Demehri, Bob S. Carter, William T. Curry, Stefanie R. Bailey, Ana P. Castano, Brian V. Nahed, Mark B. Leick, Marcela V. Maus, Irene Scarfò, Curtis L. Cetrulo, Andrea Schmidts, Hiroaki Wakimoto, Rebecca C. Larson, Amanda A. Bouffard, Xiaoling Yu, Daniel P. Cahill, Angela C. Boroughs, Matthew J. Frigault
Publikováno v:
Nature Biotechnology. 37:1049-1058
Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to heterogeneous target antigen expression and outgrowth of tumors lacking the antigen targeted by CAR-T cells directed against single antigens. Here, we developed a bicis
Publikováno v:
Autoimmunity
BACKGROUND AIM: T-Cell immunotherapies are rapidly gaining grounds in clinical success. Presently, there is first-to-market knowledge on the translation of research scale methods to clinical and commercial scales. Improved understanding can lead to m